title: Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides.
abstract: Increasing rituximab prescription for ANCA-associated necrotizing vasculitides justifies the publication of recommendations for clinicians. Rituximab is approved in the United States to induce and maintain remission. In Europe, rituximab was recently approved for remission induction. However, governmental agencies' approvals cannot replace clinical practice guidelines. Herein, the French Vasculitis Study Group Recommendations Committee, comprised of physicians with extensive experience in the treatment of vasculitides, presents its consensus guidelines based on literature analysis, the results of prospective therapeutic trials and personal experience.
authors.affiliation: Cochin hospital, AP-HP, university of Paris Descartes, department of internal medicine, 75014 Paris, France; Institute Mutualiste Montsouris, department of internal medicine, 75014 Paris, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Charles
authors.forename: Boris
authors.initials: B
authors.lastname: Bienvenu
authors.forename: Bernard
authors.initials: B
authors.lastname: Bonnotte
authors.forename: Pierre
authors.initials: P
authors.lastname: Gobert
authors.forename: Pascal
authors.initials: P
authors.lastname: Godmer
authors.forename: Éric
authors.initials: É
authors.lastname: Hachulla
authors.forename: Mohamed
authors.initials: M
authors.lastname: Hamidou
authors.forename: Jean-Robert
authors.initials: JR
authors.lastname: Harlé
authors.forename: Alexandre
authors.initials: A
authors.lastname: Karras
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Lega
authors.forename: Alain
authors.initials: A
authors.lastname: Le Quellec
authors.forename: Alfred D
authors.initials: AD
authors.lastname: Mahr
authors.forename: Luc
authors.initials: L
authors.lastname: Mouthon
authors.forename: Thomas
authors.initials: T
authors.lastname: Papo
authors.forename: Xavier
authors.initials: X
authors.lastname: Puéchal
authors.forename: Gregory
authors.initials: G
authors.lastname: Pugnet
authors.forename: Maxime
authors.initials: M
authors.lastname: Samson
authors.forename: Jean
authors.initials: J
authors.lastname: Sibilia
authors.forename: Benjamin
authors.initials: B
authors.lastname: Terrier
authors.forename: Frederick
authors.initials: F
authors.lastname: Vandergheynst
authors.forename: Loïc
authors.initials: L
authors.lastname: Guillevin
mesh_terms: D000328:Adult; D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000628:therapy*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D004502:Education, Medical, Continuing; D005602:France; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007167:Immunotherapy / Q000331:legislation & jurisprudence / Q000379:methods; D060828:Induction Chemotherapy / Q000379:methods; D060046:Maintenance Chemotherapy / Q000379:methods; D011446:Prospective Studies; D000069283:Rituximab; D012955:Societies, Medical / Q000331:legislation & jurisprudence; D011795:Surveys and Questionnaires; D014657:Vasculitis / Q000209:etiology / Q000628:therapy
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D000069283:Rituximab